Low and intermediate grade brain tumour are universally fatal brain tumours with almost no access to clinical trials. LUMOS is a comprehensive Australian trials program for these patients. We will match tumours on a molecular level with the best treatments. We will assist in accessing these drugs, including creating trials of new treatments. Lastly, we will collect an invaluable set of tissue and blood before and after treatment for future research into better treatments.

See ANZCTR for full trial details >

 

Trial Summary:

To perform a pilot study on patients with progressive G2/3 glioma after treatment with radiotherapy and chemotherapy, who consent to resection of tissue for molecular typing or analysis of tissue resected at surgery within six months prior to enrolment, with a view of treatment with matched targeted agents where available, or else treatment with standard of care therapies.

Supported by:

MRFF grant, COGNO, NHMRC CTC

Eligibility:

Adults, aged 18 years and older, with histological confirmed grade 2 or 3 glioma at initial diagnosis

Registration ID:

ACTRN12620000087954

Participation:

Australia

Australian Lead Group:

COGNO

Status:

In follow-up

Activation Date:

21/04/2020

Chairs:

A/Prof Hui Gan

Contact:

lumos.study@sydney.edu.au